Safety and pharmacokinetics of oral Cannabidiol when administered concomitantly with intravenous Fentanyl in humans

Journal of Addiction Medicine

Volumn 9, Issue 3, 2015, Pages 204-210

  Manini, Alex F ^a   Yiannoulos, Georgia ^a   Bergamaschi, Mateus M ^b   Hernandez, Stephanie ^a   Olmedo, Ruben ^a   Barnes, Allan J ^c   Winkel, Gary ^a   Sinha, Rajita ^d   Jutras Aswad, Didier ^e   Huestis, Marilyn A ^c   Hurd, Yasmin L ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

cannabidiol; cannabis; opioid dependence; pharmacokinetics

Indexed keywords

CANNABIDIOL; FENTANYL; OPIATE; PLACEBO; INTRAVENOUS ANESTHETIC AGENT;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD PRESSURE; BLURRED VISION; BREATHING RATE; BRUXISM; COMPENSATION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIAPHORESIS; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EXPOSURE; DRUG MEGADOSE; DRUG POTENCY; DRUG SAFETY; FEMALE; HEADACHE; HEART RATE; HUMAN; HUMAN EXPERIMENT; LOW DRUG DOSE; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NORMAL HUMAN; OUTCOME ASSESSMENT; OXYGEN SATURATION; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SINGLE DRUG DOSE; SUBSTANCE USE; SYSTEMATIC ASSESSMENT FOR TREATMENT EMERGENT EVENT; TERTIARY HEALTH CARE; TIME TO MAXIMUM PLASMA CONCENTRATION; VITAL SIGN; VOMITING; XEROSTOMIA; BLOOD; CLINICAL TRIAL; DRUG INTERACTION; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ADULT; ANESTHETICS, INTRAVENOUS; CANNABIDIOL; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; FEMALE; FENTANYL; HUMANS; INFUSIONS, INTRAVENOUS; MALE;

EID: 84942804432     PISSN: 19320620     EISSN: 19353227     Source Type: Journal    
DOI: 10.1097/ADM.0000000000000118     Document Type: Article

References (39)

1. Agurell S, Carlsson S, Lindgren JE, et al. Interactions of delta 1-Tetrahydrocannabinol with cannabinol and cannabidiol following oral administration in man. Assay of cannabinol and cannabidiol by mass fragmentography. Experientia 1981;37:1090-1092.
2. Bergamaschi MM, Barnes A, Queiroz RH, et al. Impact of enzymatic and alkaline hydrolysis on CBD concentration in urine. Anal Bioanal Chem 2013;405:4679-4689.
3. Bisogno T, Hanus L, De Petrocellis L, et al. Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol 2001;134:845-852.
4. Borgwardt SJ, Allen P, Bhattacharyya S, et al. Neural basis of delta-9-Tetrahydrocannabinol and cannabidiol: effects during response inhibition. Biol Psychiatry 2008;64:966-973.
5. Consroe P, Kennedy K, Schram K. Assay of plasma cannabidiol by capillary gas chromatography/ion trap mass spectroscopy following high-dose repeated daily oral administration in humans. Pharmacol Biochem Behav 1991a;40:517-522.
6. Consroe P, Laguna J, Allender J, et al. Controlled clinical trial of cannabidiol in Huntingtons disease. Pharmacol Biochem Behav 1991b;40:701-708.
7. Crippa JA, Derenusson GN, Ferrari TB, et al. Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: A preliminary report. J Psychopharmacol 2011;25:121-130.
8. Crippa JA, Zuardi AW, Garrido GE, et al. Effects of cannabidiol (CBD) on regional cerebral blood flow. Neuropsychopharmacology 2004;29:417-426.
9. Dijkstra BA, De Jong CA, Bluschke SM, et al. Does naltrexone affect craving in abstinent opioid-dependent patients? Addict Biol 2007;12:176-182.
10. Ellgren M, Spano SM, Hurd YL. Adolescent cannabis exposure alters opiate intake and opioid limbic neuronal populations in adult rats. Neuropsychopharmacology 2007;32:607-615.
11. Englund A, Morrison PD, Nottage J, et al. Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment. J Psychopharmacol 2013;27:19-27.
12. Fatseas M, Denis C, Massida Z, et al. Cue-induced reactivity, cortisol response and substance use outcome in treated heroin dependent individuals. Biol Psychiatry 2011;70:720-727.
13. Fusar-Poli P, Crippa JA, Bhattacharyya S, et al. Distinct effects of {delta}9-Tetrahydrocannabinol and cannabidiol on neural activation during emotional processing. Arch Gen Psychiatry 2009;66:95-105.
14. Glare PA, Walsh TD. Clinical pharmacokinetics of morphine. Ther Drug Monit 1991;13:1-23.
15. Karschner EL, Barnes AJ, Lowe RH, et al.Validation of a two-dimensional gas chromatography mass spectrometry method for the simultaneous quantification of cannabidiol, 9-Tetrahydrocannabinol (THC), 11-hydroxy-THC and 11-nor-9-carboxy-THC in plasma. Anal Bioanal Chem 2010;397:603-611.
16. Kathmann M, Flau K, Redmer A, et al. Cannabidiol is an allosteric modulator at mu-And delta-opioid receptors. Naunyn Schmiedebergs Arch Pharmacol 2006;372:354-361.
17. Katsidoni V, Anagnostou I, Panagis G. Cannabidiol inhibits the rewardfacilitating effect of morphine: involvement of 5-HT1A receptors in the dorsal raphe nucleus. Addict Biol 2013;18:286-296.
18. Levine J, Schooler NR. SAFTEE: A technique for the systematic assessment of side effects in clinical trials. Psychopharmacol Bull 1986;22: 343-381.
19. Leweke FM, Piomelli D, Pahlisch F, et al. Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry 2012;2:e94.
20. Massi P, Solinas M, Cinquina V, et al. Cannabidiol as potential anticancer drug. Br J Clin Pharmacol 2013;75:303-312.
21. Mecha M, Felíu A, Iñigo PM, et al. Cannabidiol provides long-lasting protection against the deleterious effects of inflammation in a viral model of multiple sclerosis: A role for A2A receptors. Neurobiol Dis 2013;59:141-150.
22. Mechoulam R, Peters M, Murillo-Rodriguez E, et al. Cannabidiol-recent advances. Chem Biodivers 2007;4:1678-92.
23. Müller-VahlKR, Emrich HM.Cannabis and schizophrenia: Towards a cannabinoid hypothesis of schizophrenia. Expert Rev Neurother 2008;8:1037-1048.
24. Pertwee RG, Ross RA, Craib SJ, et al. Cannabidiol antagonizes cannabinoid receptor agonists and noradrenaline in the mouse vas deferens. Eur J Pharmacol 2002;456:99-106.
25. Qin N, Neeper MP, Liu Y, et al. TRPV2 is activated by cannabidiol and mediates CGRP release in cultured rat dorsal root ganglion neurons. J Neurosci 2008;28:6231-6238.
26. Reid MJ, Bornheim LM. Cannabinoid-induced alterations in brain disposition of drugs of abuse. Biochem Pharmacol 2001;61:1357-1367.
27. Ren Y, Whittard J, Higuera-Matas A, et al. Cannabidiol, a nonpsychotropic component of cannabis, inhibits cue-induced heroin seeking and normalizes discrete mesolimbic neuronal disturbances. J Neurosci 2009;29:14764-14769.
28. Rodriguez JJ, Mackie K, Pickel VM, et al. Ultrastructural localization of the CB1 cannabinoid receptor in mu-opioid receptor patches of the rat caudate putamen nucleus. J Neurosci 2001;21:823-833.
29. Rosenkrantz H, Fleischman RW, Grant RJ. Toxicity of short-Term administration of cannabinoids to rhesus monkeys. Toxicol Appl Pharmacol 1981;58:118-131.
30. Schoffelmeer AN, Hogenboom F, Wardeh G, et al. Interactions between CB1 cannabinoid and mu opioid receptors mediating inhibition of neurotransmitter release in rat nucleus accumbens core. Neuropharmacology 2006;51:773.
31. Thomas A, Baillie GL, Phillips AM, et al. Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro. Br J Pharmacol 2007;150:613-623.
32. Tomida I, Azuara-Blanco A, House H, et al. Effect of sublingual application of cannabinoids on intraocular pressure: A pilot study. J Glaucoma 2006;15:349-353.
33. Watson D, Clark LA, Tellegen A. Development and validation of brief measures of positive and negative affect: The PANAS scales. J Pers Soc Psychol 1988;54:1063-1070.
34. Zacny JP, Lichtor JL, Zaragoza JG, et al. Effects of fasting on responses to intravenous fentanyl in healthy volunteers. J Subst Abuse 1992;4: 197-207.
35. Zuardi AW, Crippa JA, Hallak JE, et al. Cannabidiol for the treatment of psychosis in Parkinsons disease. J Psychopharmacol 2009;23: 979-983.
36. Zuardi AW, Guimarães FS, Moreira AC. Effect of cannabidiol on plasma prolactin, growth hormone and cortisol in human volunteers. Braz J Med Biol Res 1993;26:213-217.
37. Zuardi AW, Hallak JE, Dursun SM, et al. Cannabidiol monotherapy for treatment-resistant schizophrenia. J Psychopharmacol 2006;20: 683-686.
38. Zuardi AW, Morais SL, Guimarães FS, et al. Antipsychotic effect of cannabidiol. J Clin Psychiatry 1995;56:485-486.
39. Zuardi AW, Shirakawa I, Finkelfarb E, et al. Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects. Psychopharmacology (Berl) 1982;76:245-250.